Skip to Main Content
Table 4—

Multivariate-adjusted HRs (95% CI) of clinical end points in patients with type 2 diabetes stratified according to eGFR and albuminuria

eGFR (ml/min per 1.73 m2)
≥9060–8930–5915–29
Cardiovascular end points     
    No albuminuria [HR (95% CI), P value] 1.00 (referent) 1.00 (0.59–1.72), P = 0.991 3.05 (1.51–6.15), P = 0.002 Not enough subjects 
    Albuminuria [HR (95% CI), P value] 1.85 (1.07–3.18), P = 0.03 1.89 (1.13–3.16), P = 0.016 1.35 (0.74–2.49), P = 0.33 5.46 (2.78–10.7), P < 0.001 
Renal end points     
    No albuminuria [HR (95% CI), P value] 1.00 (referent) 0.83 (0.35–1.96), P = 0.67 0.82 (0.12–6.22), P = 0.85 Not enough subjects 
Albuminuria [HR (95% CI), P value] 2.62 (1.31–5.26), P = 0.007 4.13 (2.19–7.78), P < 0.001 10.27 (5.52–19.11), P < 0.001 90.29 (45.80–178.03), P < 0.001 
Composite end points*     
    No albuminuria [HR (95% CI), P value] 1.00 (referent) 1.21 (0.80–1.84), P = 0.36 2.98 (1.57–5.64), P = 0.001 Not enough subjects 
    Albuminuria [HR (95% CI), P value] 2.34 (1.58–3.50), P < 0.001 2.43 (1.64–3.59), P < 0.001 3.15 (2.06–4.82), P < 0.001 16.2 (10.0–26.0), P < 0.001 
eGFR (ml/min per 1.73 m2)
≥9060–8930–5915–29
Cardiovascular end points     
    No albuminuria [HR (95% CI), P value] 1.00 (referent) 1.00 (0.59–1.72), P = 0.991 3.05 (1.51–6.15), P = 0.002 Not enough subjects 
    Albuminuria [HR (95% CI), P value] 1.85 (1.07–3.18), P = 0.03 1.89 (1.13–3.16), P = 0.016 1.35 (0.74–2.49), P = 0.33 5.46 (2.78–10.7), P < 0.001 
Renal end points     
    No albuminuria [HR (95% CI), P value] 1.00 (referent) 0.83 (0.35–1.96), P = 0.67 0.82 (0.12–6.22), P = 0.85 Not enough subjects 
Albuminuria [HR (95% CI), P value] 2.62 (1.31–5.26), P = 0.007 4.13 (2.19–7.78), P < 0.001 10.27 (5.52–19.11), P < 0.001 90.29 (45.80–178.03), P < 0.001 
Composite end points*     
    No albuminuria [HR (95% CI), P value] 1.00 (referent) 1.21 (0.80–1.84), P = 0.36 2.98 (1.57–5.64), P = 0.001 Not enough subjects 
    Albuminuria [HR (95% CI), P value] 2.34 (1.58–3.50), P < 0.001 2.43 (1.64–3.59), P < 0.001 3.15 (2.06–4.82), P < 0.001 16.2 (10.0–26.0), P < 0.001 
*

Composite end points included all-cause mortality and cardiovascular and renal end points. Covariates included age, sex, duration of diabetes, smoking, BMI, systolic blood pressure, HDL and LDL cholesterol, triglycerides, A1C, RAAS inhibition and prevalent retinopathy.

Close Modal

or Create an Account

Close Modal
Close Modal